We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Immunological Tests Are Superior for Colon Cancer Screening

By LabMedica International staff writers
Posted on 18 Jul 2013
Print article
Image: OC-Sensor fully automated fecal occult blood analyzer (Photo courtesy of Eiken Chemical).
Image: OC-Sensor fully automated fecal occult blood analyzer (Photo courtesy of Eiken Chemical).
The fecal immunochemical tests (FITs) for hemoglobin offer a number of advantages over traditional guaiac based fecal occult blood tests (gFOBTs).

The major advantage seems to come at the price of higher positivity rates and lower specificity and hence a higher load of work-up colonoscopies, which makes a final judgment of the superiority of either test difficult.

Scientists from the German Cancer Research Center (Heidelberg, Germany) compared three quantitative FITs with a gFOBT among participants of the German screening colonoscopy program. They obtained stool samples and colonoscopy reports from 2,235 participants of screening colonoscopy from 2005 to 2009. Patients willing to participate were given stool collection instructions and devices, including a small container and one test card for a gFOBT (HemOccult, Beckman Coulter; Krefeld, Germany).

The stored stool samples were assayed with two automated, enzyme-linked immunosorbent assay (ELISA) based FITs, RIDASCREEN Haemoglobin, and RIDASCREEN Haemo-/Haptoglobin Complex, (R-Biopharm AG; Darmstadt, Germany). Cut-offs for positivity was 2 μg hemoglobin per gram stool. The stool samples were further analyzed, including a third FIT, OC-SENSOR, (Eiken Chemical; Tokyo, Japan).

The enzyme-based test detected one third of all colon cancer cases, about 9% of advanced precancerous adenomas lesions, and about 5% of early precancerous lesions. In 95 out of 100 participants with negative test results, no tissue abnormalities were found in the subsequent colonoscopy. Despite the already high specificities of the gFOBT for all outcomes, ranging from 95.2% to 95.4%, specificities were even higher for each of the FITs and each outcome. With estimates between 96.8% and 97.8%, specificities with respect to the detection of any cancer or any advanced neoplasm were very high for all three FITs.

Hermann Brenner, MD, MPH, a professor of clinical epidemiology, and senior author of the study said, “For the first time we have shown by direct comparison that the diagnostic performance of immunological stool tests is significantly higher than that of the enzymatic test at the same rate of positive results. Tests for occult blood in the stool will continue to be an important part of colon cancer screening. We therefore recommend including immunological tests in cancer screening programs in Germany. Many more people would thus benefit by obtaining a life-saving clue pointing to a hidden case of cancer.” The study was published on May 22, 2013, in the European Journal of Cancer.

Related Links:

Beckman Coulter
R-Biopharm
Eiken Chemical



New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Hemoglobin Testing System
VARIANTnbs

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Protein ‘signatures’ obtained via a blood sample can be used to predict the onset of 67 diseases (Photo courtesy of Queen Mary University of London)

Protein Signatures in Blood Can Predict Risk of Developing More Than 60 Diseases

Measuring specific proteins to diagnose conditions like heart attacks, where troponin is tested, is a well-established clinical practice. Now, new research highlights the broader potential of protein measurements... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Microbiology

view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more

Pathology

view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.